Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients
NCT ID: NCT07168551
Last Updated: 2025-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
111 participants
OBSERVATIONAL
2025-10-01
2026-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Understanding the relationship between hyperuricemia and NAFLD can inform targeted therapy, such as urate-lowering treatment, to potentially slow disease progression.
3 - To examine the relationship between serum uric acid levels and liver fibrosis severity\*: Assessing the correlation between serum uric acid levels and the severity of liver fibrosis in adult obese patients with NAFLD.
4- To identify potential mechanisms underlying the association\*: Exploring the potential mechanisms by which hyperuricemia may contribute to the development and progression of NAFLD and liver fibrosis in adult obese patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut University Hospitals
NCT04482153
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
NCT05120557
Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.
NCT04435054
Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver
NCT06923215
Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLD
NCT04774302
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Obesity has been demonstrated to show a consistent link with the increased possibility of nonalcoholic fatty liver disease (NAFLD). Since both serum uric acid (SUA) and obesity are essential components of metabolic syndrome (MetS), it is uncertain whether the incidence of NAFLD results from serum uric acid, obesity, or other potential factors based on previous studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1- obese +-nafld+- fibrosis
Obese patients with non alcoholic fatty liver disease with fibrosis
*Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .
Lab methods
*Imaging Studies:* 1- Ultrasound 2 - FibroScan
Imaging
Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.
Instrument
obese +- hyperuricemia +- nfld+- fibrosis
Obese patients with hyperuricemia and non alcoholic liver disease and fibrosis
*Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .
Lab methods
*Imaging Studies:* 1- Ultrasound 2 - FibroScan
Imaging
Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.
Instrument
Healthy controls
Healthy controls
*Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .
Lab methods
*Imaging Studies:* 1- Ultrasound 2 - FibroScan
Imaging
Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.
Instrument
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
*Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .
Lab methods
*Imaging Studies:* 1- Ultrasound 2 - FibroScan
Imaging
Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.
Instrument
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2 - Body Mass Index (BMI): Obese patients with a BMI ≥ 30 kg/m²
3- Hyperuricemia : Elevated serum uric acid levels (typically \> 7 mg/dL for men and \> 6 mg/dL for women)
Exclusion Criteria
2- use of steatogenic within the past 6 months
3- positive test for hepatitis B surface antigen and hepatitis B core antibody
4- Drug induced liver injury and autoimmune hepatitis
5 - cirrhosis and other causes of liver disease
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aya Adel Mahmoud Abu Shady
Internal medicine Resident doctor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UNLF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.